Diffuse Cutaneous Systemic Sclerosis research hub
5 indexed studies · 2 currently recruiting
- ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis [HZNP-HZN-825-301]
This study is testing a new medicine, Fipaxalparant, for people with a serious skin condition called diffuse cutaneous systemic sclerosis. It aims to see if the medicine can improve lung function and other symptoms over about a year.
Romania · Austria · Germany - recruitingPHASE1, PHASE2
Controlling Hyperactive Immunity With Long-lived Lymphocytes
This study tests a new treatment, QEL-005, for severe rheumatoid arthritis and systemic sclerosis. It aims to see if it's safe and helps improve symptoms. QEL-005 uses your own modified white blood cells to calm an overactive immune system.
United Kingdom - recruitingPHASE2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
This study is looking into a new medicine called Ianalumab for people in the UK with a specific type of scleroderma called diffuse cutaneous systemic sclerosis. It aims to see if the drug is safe and helps with symptoms, compared to a dummy treatment.
United States · Argentina · Austria - ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
This study is looking at a new medicine called Fipaxalparant for people with a serious skin condition called diffuse cutaneous systemic sclerosis. It's a second-stage trial to see how well it works and if it's safe over about a year.
Portugal · Greece · Germany - active not recruitingPHASE2
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
This study looks at a new drug, tulisokibart, for people with a lung condition called interstitial lung disease (ILD) linked to scleroderma. We want to see if it's safe and helps improve the condition.
United States · Argentina · Australia